RE:RE:RE:RE:RE:RE:New Press Release - Theratechnologies Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLAThe reverse split was such a mistep in the way it was orchestrated that the end result is a total valuation disconect. The company is now a price, a 1.75$ price that in reality is 40 cents. It's not 0.7 sales multiple below the sector already low 1.5 average. Ok they need the Nasdaq.. for what.. why do you need the Nasdaq. To cut the stockprice in 3 post reverse split. To get shorted by retail speculators. Why do such a thing when you can't follow up with a good news, insider buyer, good prospects. Everything is done like an experience. Lets try this and see if it works basis. Hoping the actual trials aren't done the same way.